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Dear editor:
We read with great interest the recently published article 
by Abe et al., in the esteemed journal Cell Transplantation, 
entitled “Carbamylated Erythropoietin Ameliorates Cyclo-
sporine Nephropathy Without Stimulating Erythropoie-
sis” (1). In an experimental study on 6-week-old male 
rats, which were treated with cyclosporine (CsA), they 
found that carbamylated erythropoietin (CEPO) sup-
pressed macrophage infiltration and phenotypic alteration 
of interstitial myofibroblasts and interstitial fibrosis in the 
CsA nephropathy model. They also observed that CEPO 
administration decreased the transforming growth factor 
(TGF)-b1 mRNA levels in cyclosporine-treated kidneys. 
In this study, tubular apoptosis was persistently stimulated 
after CsA treatment, while CEPO significantly inhibited 
tubular apoptosis. They concluded that CEPO adminis-
tration reduced CsA-induced tubulointerstitial injury in 
two ways: by protection of tubular epithelial cells from 
apoptosis and inhibition of interstitial fibrosis (1). We 
congratulate Abe et al. for their work; however, we would 
like to point out our findings on the kidney-protective 
effect of erythropoietin (EPO). In a study to evaluate the 
ameliorative effects of EPO on tubular cells, we studied 
40 male Wistar rats (Ahvaz Jundishapur University of 
Medical Sciences, Ahvaz, Iran) with a weight range of 
200–250 g. They were randomly allocated to four groups 
of 10 each. Of them, there was a special group, in which 
the rats first received gentamicin (100 mg/kg) for 10 days, 
then 100 U/kg EPO [Eprex (Epoetin Alfa), Janssen Cilag, 
Ltd., Switzerland] was injected intraperitoneally for the 
next 10 days, and the rats were sacrificed at the 20th day, 
and the kidneys were removed for histopathologic study 
(2). All specimens were examined for six morphologic 
parameters including epithelial cell vacuolization, degen-
eration, tubular cell flattening, hyaline cast, tubular 
dila tation, and debris materials in tubular lumen on semi-
quantitative scores from 1 to 5, while the score of 0 was 
assigned to the normal tissue without damage (4,5). EPO 
was able to prevent the increase in serum creatinine and 
blood urea nitrogen. Furthermore, coadministration of 
gentamicin and EPO reduced effectively the kidney tis-
sue damage compared to the control group. Our study 
showed the renal protective effect of erythropoietin, 
when the drug is given in combination with gentamicin. 
However, the protective property of EPO was also evi-
dent when the drug was applied after gentamicin-induced 
tubular damage, and it was revealed that the drug was 
still effective after installation of tissue injury (2). This 
indicates that EPO may have curative effects, besides its 
preventive properties (2). Hence, the study of Abe et al. 
supported the beneficial effects of EPO in renal transplant 
patients and also supported renoprotective properties of 
EPO beyond anemia correction (2,3,5,7). Thus, EPO is a 
promising kidney-protective agent to prevent, ameliorate, 
or attenuate tubular damage induced by gentamicin or 
other nephrotoxic agents such as CsA (1,6). Interestingly, 
they showed that CEPO treatment was not accompanied 
by enhancing or reducing the hemoglobin concentration. 
Hence, to reduce CsA nephrotoxicity using EPO, espe-
cially CEPO, is a reasonable suggestion by Abe et al. (1). 
In this regard, to better understand the preventive proper-
ties of erythropoietin, more experimental or clinical stud-
ies are suggested.
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